Identifying which patients will benefit most from immune checkpoint blockade (ICB) is an important clinical challenge. A study now finds that Vδ1+ γδ T cells are associated with better response to ICB in melanoma tumors with a lower neoantigen load and shows that some effector functions of PD-1+ Vδ1+ T cells are repressed after engagement of PD-1 by PD-L1.

中文翻译：

---

γδ T 细胞作为检查点封锁的非常规目标

确定哪些患者将从免疫检查点阻断 (ICB) 中获益最多是一项重要的临床挑战。现在的一项研究发现，Vδ1+ γδ T 细胞与新抗原负载较低的黑色素瘤肿瘤中对 ICB 的更好反应相关，并表明 PD-1+ Vδ1+ T 细胞的一些效应功能在 PD-1 与 PD-L1 结合后受到抑制。